Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nexalin TechnologyNXL +0.18%38 Gross Margin % is 75.00% as of Jun. 2026, which is 5% below its 10-year median of 78.79. GuruFocus rates NXL with a GF Score™ of 38/100 and a GF Value™ of $0.66 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 804 Medical Devices & Instruments companies, Nexalin Technology ranks better than 94.65% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Nexalin Technology had a gross margin of 75.00% for the quarter that ended in Jun. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Nexalin Technology Gross Margin % Related Terms
Nexalin Technology Gross Margin % Historical Data
* Premium members only.
The historical data trend for Nexalin Technology's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NXL vs ICCM, ADGM, ALRTF: Gross Margin % Comparison
For the Medical Devices subindustry, Nexalin Technology's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nexalin Technology Gross Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nexalin Technology's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Nexalin Technology's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Nexalin Technology (NXL) has a Gross Margin % of 75.00% as of Jun. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Nexalin Technology and its competitors. This is near median its historical median of 78.79. Over the past decade, Nexalin Technology's Gross Margin % has ranged from 72.52 to 88.07. According to the industry distribution chart, Nexalin Technology ranks #43 out of 804 companies in the Medical Devices & Instruments industry, placing it in the top 5.3%.
Is Nexalin Technology's Gross Margin % too high?
Nexalin Technology's current Gross Margin % of 75.00% is near median its 10-year median of 78.79. Over the past 10 years, this metric has ranged from a low of 72.52 to a high of 88.07. The Medical Devices & Instruments industry median Gross Margin % is 52.38. Nexalin Technology's value of 75.00% is 43.2% above this industry median. Based on the distribution chart, Nexalin Technology ranks #43 out of 804 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Nexalin Technology has a GF Score™ of 38/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nexalin Technology's Gross Margin % compare to ICCM and ADGM?
According to the Medical Devices & Instruments industry distribution chart, Nexalin Technology ranks #43 out of 804 companies for Gross Margin %. This places Nexalin Technology in the top 5% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 52.38. Nexalin Technology's value of 75.00% is 43.2% above this benchmark. Historically, Nexalin Technology's own Gross Margin % has ranged from 72.52 to 88.07 over the past decade. While the company's 10-year median is 78.79 vs. the industry median of 52.38, Nexalin Technology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Devices & Instruments company?
The median Gross Margin % among Medical Devices & Instruments companies is 52.38, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nexalin Technology's current Gross Margin % of 75.00% is 43.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Nexalin Technology and its competitors. For the Medical Devices & Instruments industry, the median Gross Margin % is 52.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nexalin Technology's current Gross Margin % is 75.00%, which is near median its own 10-year median of 78.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nexalin Technology stock overvalued right now?
Based on GuruFocus' analysis, Nexalin Technology (NXL) is currently considered Possible Value Trap. The stock's GF Value™ is $0.66, compared to a current price of $0.33 — trading 49.9% below its estimated fair value. The current Gross Margin % is 75.00%, which is near median its 10-year median of 78.79 and 43.2% above the Medical Devices & Instruments industry median of 52.38. Nexalin Technology's overall GF Score™ is 38/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Nexalin Technology (NXL), the current Gross Margin % is 75.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nexalin Technology (NXL) Overvalued in 2026?
Based on GuruFocus' analysis, Nexalin Technology stock appears to be undervalued.
The current stock price of $0.33 is trading 49.9% below its estimated GF Value™ of $0.66.
GuruFocus considers Nexalin Technology to be Possible Value Trap.
Key valuation signals for NXL:
Gross Margin %: 75.00% (near median its 10-year median of 78.79)
GF Value™: $0.66 vs. price of $0.33 (49.9% below fair value)
Industry Position: 43.2% above the Medical Devices & Instruments median (#43 of 804)
No single metric tells the full story. See the NXL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
38GF Score
Get the complete analysis for NXL
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NXL has been successfully added to your 
